Barclays PLC Has $167,000 Position in Verastem, Inc. (NASDAQ:VSTM)

Barclays PLC lifted its position in Verastem, Inc. (NASDAQ:VSTM) by 546.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 55,708 shares of the biopharmaceutical company’s stock after acquiring an additional 47,094 shares during the quarter. Barclays PLC owned approximately 0.13% of Verastem worth $167,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in VSTM. FMR LLC purchased a new stake in Verastem in the 3rd quarter worth approximately $41,000. SG Americas Securities LLC purchased a new stake in Verastem during the third quarter valued at about $43,000. Apollon Wealth Management LLC lifted its stake in Verastem by 104.6% during the third quarter. Apollon Wealth Management LLC now owns 20,457 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 10,457 shares during the last quarter. Acadian Asset Management LLC purchased a new position in shares of Verastem in the 2nd quarter worth about $82,000. Finally, Rhumbline Advisers grew its position in Verastem by 4,172.0% during the second quarter. Rhumbline Advisers now owns 28,793 shares of the biopharmaceutical company’s stock valued at $86,000 after acquiring an additional 28,119 shares during the last quarter. 88.37% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on VSTM shares. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Verastem in a research note on Thursday, December 19th. StockNews.com cut shares of Verastem from a “hold” rating to a “sell” rating in a report on Tuesday, November 19th. BTIG Research upped their price target on shares of Verastem from $13.00 to $20.00 and gave the company a “buy” rating in a report on Tuesday, December 31st. Cantor Fitzgerald reissued an “overweight” rating on shares of Verastem in a report on Friday, October 18th. Finally, Mizuho upped their price objective on shares of Verastem from $7.00 to $9.00 and gave the company an “outperform” rating in a research note on Thursday, December 19th. One analyst has rated the stock with a sell rating and nine have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $13.38.

Verastem Trading Down 2.7 %

NASDAQ:VSTM opened at $6.54 on Wednesday. The stock has a market cap of $291.08 million, a price-to-earnings ratio of -2.05 and a beta of 0.24. The company has a quick ratio of 3.23, a current ratio of 3.23 and a debt-to-equity ratio of 2.77. The company’s 50 day moving average price is $4.55 and its 200-day moving average price is $3.43. Verastem, Inc. has a 52 week low of $2.10 and a 52 week high of $14.22.

Verastem (NASDAQ:VSTM) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.60) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.11. On average, equities research analysts forecast that Verastem, Inc. will post -3.16 earnings per share for the current fiscal year.

Verastem Profile

Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.